Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company developing a pipeline of cancer therapies. Co.'s primary product candidate, entinostat is a once-weekly, oral, small molecule, Class I HDAC inhibitor, which is being evaluated in the Phase 3 E2112 registrational clinical trial in combination with exemestane for hormone receptor positive, human epidermal growth factor receptor 2 negative, breast cancer, an indication for which entinostat has been granted therapy designation from the United States Food and Drug Administration. SNDX-5613, Co.'s clinical-stage product candidate, is a small molecule inhibitor of the interaction of menin with the mixed lineage leukemia protein. The SNDX stock yearly return is shown above.
The yearly return on the SNDX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SNDX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|